Chlofemanic acid veterinary grade active pharmaceutical ingredient is supplied as a free-acid crystalline powder for further processing into tablets, injections, capsules, powders, granules, premixes, and solutions. The purchase specification must state the intended dosage route, because particle size, bulk density, bioburden, and residual solvent requirements are not identical across those presentations. Commercial model designations are supplier-dependent and are usually constructed from a base API code followed by a grade suffix; for example, a micronized solid oral grade may be coded with a suffix indicating D90 near 20 µm, a coarse premix grade with D90 near 60 µm, and an injectable grade with low bioburden and D90 below 15 µm. These suffixes are not harmonized and must be verified against the certificate of analysis and a validated internal specification.

What Specification Metrics Govern Release Across All Seven Veterinary Dosage Forms?

Release testing for the unformulated free acid is controlled under supplier specifications aligned with Ph. Eur. general chapters, USP general chapters, and VICH guidance. Identification is confirmed by mid-infrared absorption spectrophotometry against a qualified reference standard using Ph. Eur. 2.2.27; chromatographic retention time from reversed-phase liquid chromatography under Ph. Eur. 2.2.29 is used for confirmation. Assay on the anhydrous basis should fall within 98.0–102.0% for tablet, capsule, injectable, and solution grades; premix and granule grades may be released at 96.0–102.0% where dilution is high and the certificate of analysis is part of a mix validation. Loss on drying by Ph. Eur. 2.2.32 should not exceed 0.5% for direct compression grades. Residue on ignition by Ph. Eur. 2.4.8 is normally controlled at not more than 0.1%. Related substances are reported by area-percent normalization; individual unspecified impurities are controlled at not more than 0.2% and total impurities at not more than 1.0%, though the registered limits in the finished veterinary medicinal product may be wider or narrower depending on toxicological qualification under VICH GL11.

For solid dosage forms, powder fineness is determined by laser diffraction or mechanical sieving. A D90 of 30 µm or less is commonly specified for direct-compression tablets and capsules to support content uniformity under USP 905; for injectable suspensions, D90 is often tightened to 15 µm or less to prevent needle blockage and to meet USP 788 particulate-matter testing after reconstitution or terminal sterilisation. Bulk density and tapped density are measured according to Ph. Eur. 2.9.34; the compressibility index and Hausner ratio derived from these values inform hopper design, feed-screw selection, and capsule-fill weight control. Batches with bulk density below 0.30 g/mL may segregate in multi-ingredient premixes; batches above 0.60 g/mL may compact in silos and require vibration-assisted discharge.

In production-scale high-shear granulation of chlofemanic acid tablets, water addition above approximately 5% w/w of dry powder mass has been associated with overwetting, screen blockage, and non-uniform granule growth because the free acid has low aqueous solubility and acts as a hydrophobic fines fraction. Dry granulation by roller compaction is therefore used when the formulation contains more than 20% chlofemanic acid. Roll force is typically set between 4 kN/cm and 6 kN/cm on a pilot-to-production roller compactor, and milled granulate is screened through a 0.8 mm conidur screen before final blending. Published data for this specific configuration is limited, and the roll-force range should be confirmed on the actual equipment because ribbed roll surface roughness and feed-screw L/D ratio materially alter granule density.

Particle-Size Distribution and Bulk-Powder Handling Boundaries

Chlofemanic acid powders and granules for oral or in-feed administration are often diluted with calcium carbonate, lactose monohydrate, or corn cob carrier. Mixing homogeneity is assessed by stratified sampling across the mixer discharge; the relative standard deviation of the active assay should not exceed 5.0% for production release, a value used as an internal specification rather than a compendial numerical requirement. When the API D50 is below 10 µm, dusting and electrostatic adhesion become significant handling constraints. In those circumstances, local exhaust ventilation and controlled relative humidity below 60% are applied to reduce particle loss and cohesive buildup on stainless steel contact surfaces.

Premix-grade material is usually larger in particle size than tablet-grade material. A coarse premix may have D90 near 60 µm, which reduces dusting but increases the risk of settling in low-density carriers. Bulk density should therefore be matched to the carrier system. For direct powders and granules, flow through a gravity-fed auger or rotary valve is monitored by measuring the compressibility index; a compressibility index above 25% indicates poor flow and may require the addition of colloidal silicon dioxide at 0.2–0.5% w/w, validated according to the finished-product mixing protocol.

Only the Free-Acid Crystal Form Is Covered by This Grade

Chlofemanic acid veterinary grade API is supplied as the undissociated acid, not as a sodium salt, meglumine salt, or co-crystal. The acid is practically insoluble in purified water; solution formulations require pH adjustment above 7.0 with sodium hydroxide, trometamol, or another alkalising agent. Alkaline solution preparation should be carried out in stainless steel vessels equipped with a pH meter calibrated at 4.01, 7.00, and 9.21 buffer points under an ISO 9001 calibration control system. The free acid is expected to dissolve more readily in ethanol and dichloromethane than in water, but the exact solubility profile must be taken from the supplier’s batch-specific data because published data for this specific configuration is limited.

When wet granulation is unavoidable, the acid should be pre-dispersed in a suitable non-aqueous solvent or introduced as a dry pre-blend with a hydrophilic filler before aqueous binder addition. Direct addition of alkaline granulating fluid onto a dry acid bed can produce localized partial salt formation, altering compact hardness and dissolution rate. Granulation endpoint is monitored by impeller torque or power consumption on the high-shear mixer; a reproducible torque rise indicates binder distribution, but the absolute torque value is equipment-specific. Drying of wet granules should be controlled so that final granule LOD returns below 0.8% before compression.

Injectable-grade chlofemanic acid is usually low-bioburden rather than terminally sterile as supplied. Before aseptic formulation, the API is dissolved and filter-sterilised through a 0.22 µm PVDF or PES membrane. If terminal sterilisation by autoclave is proposed, thermal stress studies at 121 °C for 15 min shall be performed on a pilot scale; published data for this specific configuration are limited, and the appearance of new degradation peaks above the reporting threshold of 0.1% must trigger a switch to aseptic filtration. Endotoxin control is dose-dependent and should be calculated from the finished product limit under USP 85 or Ph. Eur. 2.6.14; a typical injectable-grade API release limit is often set at not more than 0.25 EU/mg, but this value must be justified against the maximum daily dose.

When Residual Solvent Control Separates Veterinary API from Human API

Veterinary-grade release under VICH GL18 requires that residual solvents be limited to those acceptable for the route and target species. Ethanol and isopropanol are typically controlled at not more than 5000 ppm or 500 ppm depending on class; dichloromethane is controlled at the ICH/VICH limit of 600 ppm; benzene should be absent at the limit of quantification. The numerical limits are identical to ICH Q3C for human API in many cases, but veterinary-specific exposure scenarios may allow a different safety margin only when justified by species metabolism data. Buyers should not assume a human residual-solvent certificate of analysis is transferable to a veterinary premix; the route-specific daily intake and target species must be evaluated under VICH GL18.

Differences from other fenamate-class APIs and salt forms are therefore not limited to potency. The free acid is not interchangeable on a mass basis with a sodium or meglumine salt, because a stoichiometric correction factor is required for dosage equivalence. The free acid may be preferred for tablets, capsules, dry powders, and premixes, whereas a soluble salt is commonly needed for aqueous injection or solution formulations. Conversion from the free acid to a salt in situ is possible but introduces pH-dependent stability risk. In addition, other fenamate APIs such as tolfenamic acid, meclofenamic acid, and flufenamic acid are distinct chemical entities; their substitution patterns affect pKa, lipophilicity, chromatographic retention time, and melting range. Pharmacopoeial reference standards are therefore not interchangeable, and analytical methods should be developed specifically for chlofemanic acid rather than transferred from a related fenamate monograph.

For capsules and tablets, the API is commonly dry-blended with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. Blend uniformity is verified by sampling at least 10 locations using a unit-dose sample thief; assay variability is then compared against USP 905 content uniformity acceptance criteria. If the API fraction is less than 5% of the core weight, a premix step with geometric dilution is required. Tablet compression should be monitored for ejection force, hardness, and friability using USP 1216 for tablet friability and USP 1217 for tablet breaking force. Capsule filling may require a low-dust grade with controlled static charge; empty capsule shells should be conditioned at 20–25 °C and 40–50% RH before filling to reduce deformation.

For solutions, the formulation vehicle typically consists of water for injection, a preservative if multidose, a chelating agent, and a pH-adjusting buffer. Dissolution of the free acid requires alkalisation; the final solution is usually filtered through a 0.45 µm prefilter and a 0.22 µm sterilising-grade membrane. Filter compatibility must be evaluated because low-concentration solutions may show adsorptive loss on nylon membranes; PVDF or PES membranes are preferred. Packaging in Amber Type I glass or opaque multilayer plastic is used where light exposure is a stability risk; published data for this specific API-packaging configuration is limited, so a photostability study under ICH Q1B conditions is necessary before commercial batch release.

For granules and premixes, the finished blend is often filled into foil-lined multi-wall bags or HDPE drums. Moisture ingress above 60% RH can increase the cohesiveness of the dry blend and reduce flow; desiccant sachets are used where justified by sorption isotherm data. If the premix is intended for subsequent pelleting or extrusion, the thermal processing window should be validated because the active may degrade at elevated temperatures. A twin-screw extruder with barrel temperatures set at 70–90 °C is often used for medicated feed pellets, but the specific temperature profile must be established by impurity analysis after extrusion. The free acid may also interact with alkaline minerals such as divalent calcium carbonate; this requires a compatibility study for blend stability and assay recovery.

Chlofemanic acid veterinary grade API for tablets, injections, capsules, powders, granules, premixes, and solutions therefore requires route-specific physical grading, analytical release testing, and processing controls. The product is not a single universal powder; it is a family of grades differentiated by particle size, bioburden, and residual solvent profile. Manufacturers preparing multiple dosage forms should establish separate internal specifications for each route and avoid using one grade across all applications without verifying blend homogeneity, dissolution, filterability, and chemical stability. The absence of harmonized public monographs for this specific veterinary API means that supplier data, toxicological qualification, and production-scale trial batches provide the primary basis for setting release limits and processing boundaries.